<DOC>
	<DOCNO>NCT03090737</DOCNO>
	<brief_summary>A study evaluate safety Nivolumab patient advance metastatic non-small cell lung cancer</brief_summary>
	<brief_title>Safety Study Nivolumab Treat Advanced Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Non small cell lung cancer ( Squamous nonsquamous ) One prior anticancer therapy work ECOG Performance Scale 01 Cancer spread brain leptomeninges unless evidence progression MRI 8 week treatment complete within 28 day first dose study drug Active , know suspected autoimmune disease infection Prior immunooncology therapy Corticosteroids within 2 week study drug administration Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>